Pharma BD Deal Intelligence
A licensing/option deal (not an acquisition), $63M upfront against $1.7B in milestones for Lilly to access Sigilon's Shielded Living encapsulated cell therapy platform in Type 1 diabetes—still pre-clinical stage risk, with the low outcome score reflecting the platform's failure to advance rather than a straightforward win.
Lilly takes over partner Sigilon working on cell therapies for diabetes began with 2018 Afibromer collaboration.
Lilly acquired Sigilon its cell therapy partner after initial 2018 collaboration worth $63M upfront plus $410M milestones.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Lilly licensed Sigilon's Shielded Living Therapeutics platform for Type 1 diabetes cell therapy, paying $63M upfront with up to $1.7B in milestones.
64K US cases/yr · $12.0B Global Type 1 diabetes therapeutics (insulin + advanced tech)
Type 1 diabetes is an autoimmune condition destroying insulin-producing beta cells. Beyond insulin, cell therapy and encapsulated islet approaches aim for functional cure. Teplizumab (Tzield) approved to delay T1D onset in at-risk individuals.
Insulin therapy (rapid-acting, long-acting, pumps, closed-loop systems). Disease modification: teplizumab (Tzield, Provention Bio/Sanofi). Cell therapy: Lantidra (donislecel), Vertex VX-880 (stem cell-derived islets). Key players: Novo Nordisk, Lilly, Sanofi, Vertex.
Lilly paid $63M upfront for SIG-002 encapsulated cell therapy for T1 diabetes. Up to $1.7B milestones.
Lilly bought Sigilon ($14.92/share + CVR up to $111.64). Collaboration converted to full acquisition.
Collaboration led to $309M acquisition. SIG-002 program continued under Lilly. Bargain-bin pricing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Sigilon Therapeutics Inc. (this deal) | 2018 | $1.8B | 31 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2018 deals · Eli Lilly and Company deals · Cardiovascular deals